Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (8)	1/18/1998 9:22:00 PM
From: Cary C	Read Replies (1) \| Respond to of 29382

OLGC.... Sergio it appears that new management is taking a conservative and cautious approach when reporting company numbers. I personally like this. In briefly reviewing the last two quarters numbers, biz.yahoo.com biz.yahoo.com it was particularly interesting to note the selling and G/A expenses in comparison to revenues. The last two quarters revenues were prety much the same (a little over 18 million)yet there was a decrease of approximately 2 million in S & G/A expenses. With the one time charges taken care of and if they can continue reducing S & G/A expenses, I would have to agree with Mike Hodge in that the worst might very well be over. From previous filings, it looks like they might be getting ready to report year end earnings fairly soon. Sergio or Mike's do you have any idea how much the fees would be pertaining to this clip from the news release >>>The cost of performing pre-clinical and clinical trials will be funded by OrthoLogic. OrthoLogic will pursue commercialization of Chrysalin, initially seeking Food and Drug Administration approval for human clinical trials for the fracture-healing indication. OrthoLogic projects that Chrysalin could receive all necessary FDA approvals and be introduced in the market during 2000. <<<< Cary